Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Paper-Based Portable Diagnostic Platform Accurately Detects Mosquito-Borne Diseases Under Field Conditions

By LabMedica International staff writers
Posted on 09 Mar 2022

Field trails conducted in Latin America have shown that a paper-based portable diagnostic platform could accurately detect patients with mosquito-borne diseases with sensitivities equivalent to laboratory PCR tests. More...

In low-resource settings, resilience to infectious disease outbreaks can be hindered by limited access to diagnostic tests. In response to this limitation, investigators at the University of Toronto (Canada) and the biotech company LSK Technologies (Toronto, Canada) developed a portable diagnostic platform that was a combination of a cell-free, paper-based test and a field-ready companion device that allowed data to be collected using image-based color analysis. Called “PLUM” (Portable, Low-cost, User-friendly, Multimode), the conveniently-sized reader presented results from up to 384 samples and displayed them in a single image capture.

In the initial studies, the platform was optimized for detection of first Zika and then chikungunya viruses with reagents that could be freeze-dried, allowing for distribution without refrigeration

Using RNA extracted from the serum of patient samples collected in Brazil, the investigators found that the combined PLUM reader and paper-based Zika sensor provided analytical sensitivity and specificity for the Zika virus equivalent to RT–qPCR (quantitative real-time PCR) with a diagnostic accuracy of 98.5%. The investigators then demonstrated that by simply changing the molecular components that confer specificity to the assay, they could detect the chikungunya virus with 98.5% accuracy.

“We see emerging diagnostics, like the paper-based tests we have developed, as having tremendous near-term potential to augment existing PCR capacity, improve equity in access to health care, and aid in the responses to public health crises,” said senior author Dr. Keith Pardee, assistant professor of pharmaceutical sciences at the University of Toronto.

A sticking point delaying the field use of the PLUM system is that the extraction of RNA from patient samples requires liquid handling by skilled technicians. “With performance on patient samples now validated, we are tackling these next challenges, like sample preparation, so that the platform and PCR-like diagnostic capacity can be distributed more broadly into the communities where they are needed,” said Dr. Pardee.

The Zika virus field test was described in the March 7, 2022, online edition of the journal Nature Biomedical Engineering.

Related Links:
University of Toronto 
LSK Technologies 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.